Literature DB >> 21090930

Pulmonary hypertension in women.

Meredith E Pugh1, Anna R Hemnes.   

Abstract

Female predominance in pulmonary arterial hypertension (PAH) has been known for several decades and recent interest in the effects of sex hormones on the development of disease has substantially increased our understanding of this epidemiologic observation. Basic science data suggest a beneficial effect of estrogens in the pulmonary vasculature both acutely and chronically, which seems to contradict the known predilection in women. Recent human and rodent data have suggested that altered levels of estrogen, differential signaling and altered metabolism of estrogens in PAH may underlie the gender difference in this disease. Studies of the effects of sex hormones on the right ventricle in animal and human disease will further aid in understanding gender differences in PAH. This article focuses on the effects of sex hormones on the pulmonary vasculature and right ventricle on both a basic science and translational level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21090930      PMCID: PMC3077035          DOI: 10.1586/erc.10.137

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  92 in total

1.  Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I).

Authors:  Nicholas Collins; Bruce Bastian; Laurent Quiqueree; Carol Jones; Renae Morgan; Glenn Reeves
Journal:  Eur J Echocardiogr       Date:  2006-01-20

2.  BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity.

Authors:  Cristina Gamell; Nelson Osses; Ramon Bartrons; Thomas Rückle; Montserrat Camps; José Luis Rosa; Francesc Ventura
Journal:  J Cell Sci       Date:  2008-11-11       Impact factor: 5.285

3.  Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.

Authors:  Richard N Channick; Horst Olschewski; Werner Seeger; Ted Staub; Robert Voswinckel; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2006-09-14       Impact factor: 24.094

4.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Authors:  Mette Sørensen; Herman Autrup; Anne Tjønneland; Kim Overvad; Ole Raaschou-Nielsen
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

Review 5.  Functional role of estrogen metabolism in target cells: review and perspectives.

Authors:  B T Zhu; A H Conney
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

6.  Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension.

Authors:  Beata Wojciak-Stothard; Lillian Yen Fen Tsang; Ewa Paleolog; Susan M Hall; Sheila G Haworth
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-01-20       Impact factor: 5.464

7.  Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle.

Authors:  Tim Lahm; Ketan M Patel; Paul R Crisostomo; Troy A Markel; Meijing Wang; Christine Herring; Daniel R Meldrum
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-06-26       Impact factor: 4.310

8.  Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.

Authors:  James West; Karen Fagan; Wolfgang Steudel; Brian Fouty; Kirk Lane; Julie Harral; Marloes Hoedt-Miller; Yuji Tada; John Ozimek; Rubin Tuder; David M Rodman
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

9.  Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism.

Authors:  Tim Lahm; Paul R Crisostomo; Troy A Markel; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-01       Impact factor: 3.619

10.  Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.

Authors:  Alyson M Smith; Robert T Bennett; T Hugh Jones; Mike E Cowen; Kevin S Channer; Richard D Jones
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  14 in total

Review 1.  [Gender aspects in anesthesia : modified approach in research and treatment?].

Authors:  M Schopper; P I Bäumler; J Fleckenstein; D Irnich
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

2.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

3.  Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening.

Authors:  Jennifer Rusiecki; Youlan Rao; Jody Cleveland; Zachary Rhinehart; Hunter C Champion; Michael A Mathier
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 4.  Physiological aspects of cardiopulmonary dysanapsis on exercise in adults born preterm.

Authors:  Joseph W Duke; Adam J Lewandowski; Steven H Abman; Andrew T Lovering
Journal:  J Physiol       Date:  2022-01-12       Impact factor: 6.228

Review 5.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

6.  Roles of Genetic Predisposition in the Sex Bias of Pulmonary Pathophysiology, as a Function of Estrogens : Sex Matters in the Prevalence of Lung Diseases.

Authors:  An Huang; Sharath Kandhi; Dong Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Using all-cause mortality to define severe RV dilation with RV/LV volume ratio.

Authors:  Stephan P L Altmayer; Q Joyce Han; Karima Addetia; Amit R Patel; Paul R Forfia; Yuchi Han
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

8.  Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.

Authors:  Mengtao Li; Zhi-Cheng Jing; Yang Li; Yong Huo; Zaixin Yu; Gangcheng Zhang; Ping Zhu; Jinming Liu; Qiushang Ji; Bingxiang Wu; Jinhua Zhong; Pingping Wang; Wenjing Zhu; Xiaofeng Zeng
Journal:  BMC Cardiovasc Disord       Date:  2020-07-17       Impact factor: 2.298

9.  Women with hypertrophic cardiomyopathy have worse survival.

Authors:  Jeffrey B Geske; Kevin C Ong; Konstantinos C Siontis; Virginia B Hebl; Michael J Ackerman; David O Hodge; Virginia M Miller; Rick A Nishimura; Jae K Oh; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen
Journal:  Eur Heart J       Date:  2017-12-07       Impact factor: 29.983

10.  Lumped-parameter models of the pulmonary vasculature during the progression of pulmonary arterial hypertension.

Authors:  Jesse W Gerringer; Julie C Wagner; Daniela Vélez-Rendón; Daniela Valdez-Jasso
Journal:  Physiol Rep       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.